🇺🇸 FDA

Intelligence · Clinical Pipeline

Novartis India Pipeline

All ClinicalTrials.gov programs at Novartis India — phase, modality, and trial IDs.

Programs
341

Quick answer

Novartis India has 341 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

  1. Kesimpta 20 mg solution for injection in pre-filled pen, Kesimpta 20 mg solution for injection in pre-filled pen

    Novartis Pharmaceuticals

    relapsing multiple sclerosis (RMS)

    phase 3 small molecule active

    1 trial

  2. LCZ696 (sacubitril/valsartan)

    Novartis Pharmaceuticals

    Acute Myocardial Infarction

    phase 3 small molecule completed

    1 trial

  3. LEUPRORELIN ACETATE, LEUPRORELIN ACETATE, ANASTROZOLE, GOSERELIN, LETROZOLE, GOSERELIN, EXEMESTANE, RIBOCICLIB

    Novartis Pharmaceuticals

    HR-positive HER-2- negative Breast Cancer

    phase 3 small molecule active

    1 trial

  4. LMF237 50/250 mg

    Novartis Pharmaceuticals

    Diabetes Mellitus, Type 2

    phase 3 small molecule completed

    1 trial

  5. LNP023

    Novartis Pharmaceuticals

    Primary IgA Nephropathy

    phase 3 small molecule active

    1 trial

  6. LOU064

    Novartis Pharmaceuticals

    Chronic Spontaneous Urticaria

    phase 3 small molecule active

    1 trial

  7. LOU064 (blinded)

    Novartis Pharmaceuticals

    Chronic Spontaneous Urticaria

    phase 3 small molecule completed

    1 trial

  8. LOU064, CLINDAMYCIN , Placebo to remibrutinib (lou064) 0 mg matching 00 mg film-coated tablet, LOU064, Placebo to remibrutinib (lou064) 0 mg matching 00 mg film-coated tablet, TRIAMCINOLONE , -

    Novartis Pharmaceuticals

    Hidradenitis Suppurativa (HS)

    phase 3 small molecule active

    1 trial

  9. LOU064, COLESTYRAMINE , TERIFLUNOMIDE, Placebo to teriflunomide 14 mg capsule, hard, Placebo to Remibrutinib (LOU064) 100 mg film-coated tablet, MEDICINAL CHARCOAL

    Novartis Pharmaceuticals

    Multiple Sclerosis

    phase 3 small molecule active

    1 trial

  10. LOU064, Placebo to Remibrutinib (LOU064) XX mg film-coated tablet, -, -

    Novartis Pharmaceuticals

    Chronic Inducible Urticaria (CINDU)

    phase 3 small molecule active

    1 trial

  11. LOU064, Placebo to teriflunomide 14 mg capsule, hard, COLESTYRAMINE , Placebo to Remibrutinib (LOU064) 100 mg film-coated tablet, TERIFLUNOMIDE, MEDICINAL CHARCOAL

    Novartis Pharmaceuticals

    Multiple Sclerosis

    phase 3 small molecule active

    1 trial

  12. Lapatinib

    Novartis Pharmaceuticals

    Breast Neoplasms

    phase 3 small molecule completed

    1 trial

  13. Lapatinib

    Novartis Pharmaceuticals

    Neoplasms, Breast

    phase 3 small molecule terminated

    2 trials

  14. Ligelizumab

    Novartis Pharmaceuticals

    Chronic Spontaneous Urticaria

    phase 3 mab completed

    1 trial

  15. Locametz 25 micrograms kit for radiopharmaceutical preparation, ABIRATERONE , LEUPRORELIN , HISTRELIN , ENZALUTAMIDE , TRIPTORELIN , NILUTAMIDE , Pluvicto 1 000 MBq/mL solution for injection/infusion, GOSERELIN , DEGARELIX , BICALUTAMIDE , BUSERELIN , -, RELUGOLIX , APALUTAMIDE , DAROLUTAMIDE , FLUTAMIDE

    Novartis Pharmaceuticals

    PSMA-positive metastatic hormone-sensitive prostate cancer (mHSPC)

    phase 3 small molecule active

    1 trial

  16. Locametz 25 micrograms kit for radiopharmaceutical preparation, PIFLUFOLASTAT (18F), PIFLUFOLASTAT (18F), Pluvicto 1 000 MBq/mL solution for injection/infusion

    Novartis Pharmaceuticals

    Oligometastatic prostate cancer (OMPC)

    phase 3 small molecule active

    1 trial

  17. METOCLOPRAMIDE , -, SANDOSTATIN LAR 10 mg powder and solvent for suspension for injection, LysaKare 25 g/25 g solution for infusion, SANDOSTATIN LAR 20 mg powder and solvent for suspension for injection, SANDOSTATIN LAR 30 mg powder and solvent for suspension for injection, Lutathera 370 MBq/mL solution for infusion, OCTREOTIDE

    Novartis Pharmaceuticals

    Gastroenteropancreatic neuroendocrine tumor (GEP-NET)

    phase 3 small molecule active

    1 trial

  18. MYCOPHENOLIC ACID, -, MYCOPHENOLATE MOFETIL, VAY736, TENOFOVIR ALAFENAMIDE , ENTECAVIR , TENOFOVIR DISOPROXIL

    Novartis Pharmaceuticals

    Lupus nephritis

    phase 3 small molecule active

    1 trial

  19. MYCOPHENOLIC ACID, TENOFOVIR ALAFENAMIDE , Placebo to VAY736 150 mg/1 mL Solution for injection in pre-filled syringe , Placebo to VAY736 300 mg/2 mL Solution for injection in pre-filled syringe, VAY736, ENTECAVIR , -, TENOFOVIR DISOPROXIL , VAY736, MYCOPHENOLATE MOFETIL

    Novartis Pharmaceuticals

    Lupus nephritis

    phase 3 small molecule active

    1 trial

  20. NILOTINIB, ASCIMINIB HYDROCHLORIDE, NILOTINIB, NILOTINIB

    Novartis Pharmaceuticals

    Chronic Myeloid Leukemia

    phase 3 small molecule active

    1 trial

  21. NIO752, Isotone Kochsalz-Lösung 0,9 % Braun Infusionslösung

    Novartis Pharmaceuticals

    Participants with Progressive Supranuclear Palsy Richardson Syndrome (PSP-RS)

    phase 3 small molecule active

    1 trial

  22. NIS793

    Novartis Pharmaceuticals

    Metastatic Pancreatic Ductal Adenocarcinoma

    phase 3 small molecule completed

    1 trial

  23. Nilotinib

    Novartis Pharmaceuticals

    Chronic Myeloid Leukemia

    phase 3 small molecule completed

    1 trial

  24. Nilotinib (AMN107)

    Novartis Pharmaceuticals

    Gastrointestinal Stromal Tumor (GIST)

    phase 3 small molecule completed

    1 trial

  25. OAV101

    Novartis Pharmaceuticals

    Spinal Muscular Atrophy

    phase 3 gene therapy completed

    1 trial

  26. OAV101B, Zolgensma 2 × 10^13 vector genomes/mL solution for infusion

    Novartis Pharmaceuticals

    Spinal Muscular Atrophy

    phase 3 small molecule active

    1 trial

  27. OCRELIZUMAB, LOU064, OCRELIZUMAB

    Novartis Pharmaceuticals

    Relapsing multiple sclerosis

    phase 3 small molecule active

    1 trial

  28. OFC Infusion

    Novartis Pharmaceuticals

    Leukaemia, Lymphocytic, Chronic

    phase 3 small molecule completed

    1 trial

  29. Ofatumumab

    Novartis Pharmaceuticals

    Leukaemia, Lymphocytic, Chronic

    phase 3 mab terminated

    1 trial

  30. PACLITAXEL, ALPELISIB, DOXORUBICIN HYDROCHLORIDE, OLAPARIB, ALPELISIB, OLAPARIB

    Novartis Pharmaceuticals

    Platinum-resistant or refractory, high-grade serous ovarian cancer with no germline BRCA mutation

    phase 3 small molecule active

    1 trial

  31. PREDNISONE, Placebo to AIN457 150mg/1mL solution for injection in pre-filled syringe, SECUKINUMAB, PREDNISONE, Placebo to Prednisone 1 mg, 2.5mg, 5mg, 20mg hard gelatin capsule with tablet content, PREDNISONE, PREDNISONE, SECUKINUMAB, Placebo to AIN457 300mg/2mL solution for injection in pre-filled syringe

    Novartis Pharmaceuticals

    Giant cell arteritis (GCA)

    phase 3 small molecule active

    1 trial

  32. Panobinostat

    Novartis Pharmaceuticals

    Multiple Myeloma

    phase 3 small molecule completed

    1 trial

  33. Pelacarsen

    Novartis Pharmaceuticals

    Atherosclerotic Cardiovascular Disease (ASCVD)

    phase 3 small molecule active

    1 trial

  34. Placebo

    Novartis Pharmaceuticals

    IC-MPGN

    phase 3 small molecule active

    1 trial

  35. Placebo

    Novartis Pharmaceuticals

    Ankylosing Spondylitis

    phase 3 mab completed

    1 trial

  36. Placebo - Film coated tablet for oral use, atrasentan

    Novartis Pharmaceuticals

    Immunoglobulin A Nephropathy (IgAN)

    phase 3 small molecule active

    1 trial

  37. Placebo 0 mg hard gelatin capsule size 0, (placebo to LNP023 200 mg), IPTACOPAN

    Novartis Pharmaceuticals

    IgA Nephropathy

    phase 3 small molecule active

    1 trial

  38. Placebo 0 mg hard gelatin capsule size 0, (placebo to LNP023), IPTACOPAN

    Novartis Pharmaceuticals

    generalized Myasthenia Gravis

    phase 3 small molecule active

    1 trial

  39. Placebo 0 mg hard gelatin capsule size 1, (placebo to lnp023 100 mg), Placebo 0 mg hard gelatin capsule size 0, (placebo to lnp023 200 mg), IPTACOPAN HYDROCHLORIDE, IPTACOPAN

    Novartis Pharmaceuticals

    complement 3 glomerulopathy

    phase 3 small molecule active

    1 trial

  40. Placebo 0 mg/1 mL Solution for infusion/injection, VAY736

    Novartis Pharmaceuticals

    Autoimmune hepatitis

    phase 3 small molecule active

    1 trial

  41. Placebo to AIN457 150 mg/ 1 mL Solution for injection in pre-filled syringe. This placebo is an additional/ alternative placebo to placebo to Xolair® (Omalizumab) to ensure continuous supply in the clinical trial. For more details please refer to Note to Assessor located in the “Placebo to AIN457” product shell., OMALIZUMAB , -, Placebo to Xolair® (Omalizumab) 150 mg/ml solution for injection in pre-filled syringe, LOU064, Placebo to Remibrutinib (LOU064) 25 mg film-coated tablet, -

    Novartis Pharmaceuticals

    Chronic Spontaneous Urticaria

    phase 3 small molecule active

    1 trial

  42. Placebo to AIN457 300 mg/2 mL Solution for injection in pre-filled syringe, Cosentyx 300 mg solution for injection in pre-filled syringe

    Novartis Pharmaceuticals

    Giant Cell Arteritis

    phase 3 small molecule active

    1 trial

  43. Placebo to AIN457 300mg/2mL Solution for injection in pre-filled syringe, SECUKINUMAB

    Novartis Pharmaceuticals

    Hidradenitis suppurativa

    phase 3 small molecule active

    1 trial

  44. Placebo to Remibrutinib (LOU064) 0 mg matching 00 mg film-coated tablet, TRIAMCINOLONE , Placebo to Remibrutinib (LOU064) 0 mg matching 00 mg film-coated tablet, LOU064, CLINDAMYCIN , LOU064, -

    Novartis Pharmaceuticals

    Hidradenitis Suppurativa (HS)

    phase 3 small molecule active

    1 trial

  45. Placebo to Remibrutinib (LOU064) 00 mg film-coated tablet, LOU064

    Novartis Pharmaceuticals

    Generalized Myasthenia Gravis

    phase 3 small molecule active

    1 trial

  46. Placebo to Remibrutinib (LOU064) XX mg film-coated tablet, LOU064, LOU064, Placebo to Remibrutinib (LOU064) XX mg film-coated tablet

    Novartis Pharmaceuticals

    Hidradenitis Suppurativa (HS)

    phase 3 small molecule active

    1 trial

  47. Placebo to Remibrutinib (LOU064) film-coated tablets, LOU064

    Novartis Pharmaceuticals

    Secondary progressive multiple sclerosis

    phase 3 small molecule active

    1 trial

  48. Placebo to TQJ230 80 mg/0.8 mL Solution for injection in pre-filled syringe with needle safety device, TQJ230

    Novartis Pharmaceuticals

    Cardiovascular Disease

    phase 3 small molecule active

    1 trial

Frequently asked questions

How many pipeline programs does Novartis India have?

341 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.